Columbia Laboratories (CBRX) Misses Q4 EPS by 12c

Columbia Laboratories (NASDAQ: CBRX) reported Q4 EPS of ($0.05), $0.12 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.93 million.

Columbia is actively moving forward as a women's health specialty pharmaceutical company focused on 505(b)2 products. The Company's next product will enter the clinic during the second quarter, and the Company is active in identifying and advancing additional, promising drug candidates.

For earnings history and earnings-related data on Columbia Laboratories (CBRX) click here.

You May Also Be Interested In

• Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
• S&T Bancorp (STBA) Tops Q1 EPS by 3c
• Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance